450 related articles for article (PubMed ID: 35743140)
1. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
3. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.
Miura K; Yang L; van Rooijen N; Ohnishi H; Seki E
Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(11):G1310-21. PubMed ID: 22442158
[TBL] [Abstract][Full Text] [Related]
4. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.
Parker R; Weston CJ; Miao Z; Corbett C; Armstrong MJ; Ertl L; Ebsworth K; Walters MJ; Baumart T; Newland D; McMahon J; Zhang P; Singh R; Campbell J; Newsome PN; Charo I; Schall TJ; Adams DH
Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G483-G493. PubMed ID: 29420066
[TBL] [Abstract][Full Text] [Related]
5. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
Fisher FM; Chui PC; Nasser IA; Popov Y; Cunniff JC; Lundasen T; Kharitonenkov A; Schuppan D; Flier JS; Maratos-Flier E
Gastroenterology; 2014 Nov; 147(5):1073-83.e6. PubMed ID: 25083607
[TBL] [Abstract][Full Text] [Related]
7. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
8. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Lefere S; Devisscher L; Tacke F
Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
[No Abstract] [Full Text] [Related]
9. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
[TBL] [Abstract][Full Text] [Related]
10. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
12. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.
Thapaliya S; Wree A; Povero D; Inzaugarat ME; Berk M; Dixon L; Papouchado BG; Feldstein AE
Dig Dis Sci; 2014 Jun; 59(6):1197-206. PubMed ID: 24795036
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
14. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.
Mauer AS; Hirsova P; Maiers JL; Shah VH; Malhi H
Am J Physiol Gastrointest Liver Physiol; 2017 Mar; 312(3):G300-G313. PubMed ID: 28039158
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
17. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
Baeck C; Wehr A; Karlmark KR; Heymann F; Vucur M; Gassler N; Huss S; Klussmann S; Eulberg D; Luedde T; Trautwein C; Tacke F
Gut; 2012 Mar; 61(3):416-26. PubMed ID: 21813474
[TBL] [Abstract][Full Text] [Related]
19. The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.
Mulder P; van den Hoek AM; Kleemann R
PLoS One; 2017; 12(1):e0169740. PubMed ID: 28076416
[TBL] [Abstract][Full Text] [Related]
20. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
